» Articles » PMID: 35451598

Inhibition of P38 MAPK Decreases Hyperglycemia-induced Nephrin Endocytosis and Attenuates Albuminuria

Abstract

Chronic hyperglycemia, as in diabetes mellitus, may cause glomerular damage with microalbuminuria as an early sign. Noteworthy, even acute hyperglycemia can increase glomerular permeability before structural damage of the glomerular filter can be detected. Despite intensive research, specific antiproteinuric therapy is not available so far. Thus, a deeper understanding of the molecular mechanisms of albuminuria is desirable. P38 MAPK signaling is involved in the development of hyperglycemia-induced albuminuria. However, the mechanism of increased p38 MAPK activity leading to increased permeability and albuminuria remained unclear. Recently, we demonstrated that acute hyperglycemia triggers endocytosis of nephrin, the key molecule of the slit diaphragm, and induces albuminuria. Here, we identify p38 MAPK as a pivotal regulator of hyperglycemia-induced nephrin endocytosis. Activated p38 MAPK phosphorylates the nephrin c-terminus at serine 1146, facilitating the interaction of PKCα with nephrin. PKCα phosphorylates nephrin at threonine residues 1120 and 1125, mediating the binding of β-arrestin2 to nephrin. β-arrestin2 triggers endocytosis of nephrin by coupling it to the endocytic machinery, leading to increased glomerular permeability. Pharmacological inhibition of p38 MAPK preserves nephrin surface expression and significantly attenuates albuminuria. KEY MESSAGES: Acute hyperglycemia triggers endocytosis of nephrin. Activated p38 MAPK phosphorylates the nephrin c-terminus at serine 1146, facilitating the interaction of PKCα with nephrin. PKCα phosphorylates nephrin at threonine residues 1120 and 1125, mediating the binding of β-arrestin2 to nephrin. β-arrestin2 triggers endocytosis of nephrin by coupling it to the endocytic machinery, leading to a leaky glomerular filter. Pharmacological inhibition of p38 MAPK preserves nephrin surface expression and significantly attenuates albuminuria under hyperglycemic conditions.

Citing Articles

Unveiling the pathogenesis and therapeutic approaches for diabetic nephropathy: insights from panvascular diseases.

Zhang X, Zhang J, Ren Y, Sun R, Zhai X Front Endocrinol (Lausanne). 2024; 15:1368481.

PMID: 38455648 PMC: 10918691. DOI: 10.3389/fendo.2024.1368481.


The proteasome modulates endocytosis specifically in glomerular cells to promote kidney filtration.

Sachs W, Blume L, Loreth D, Schebsdat L, Hatje F, Koehler S Nat Commun. 2024; 15(1):1897.

PMID: 38429282 PMC: 10907641. DOI: 10.1038/s41467-024-46273-0.


Titanium particles inhibit bone marrow mesenchymal stem cell osteogenic differentiation through the MAPK signaling pathway.

Tong S, Fang S, Ying K, Chen W FEBS Open Bio. 2023; 13(9):1699-1708.

PMID: 37483149 PMC: 10476562. DOI: 10.1002/2211-5463.13678.


A Cyclopentanone Compound Attenuates the Over-Accumulation of Extracellular Matrix and Fibrosis in Diabetic Nephropathy via Downregulating the TGF-β/p38MAPK Axis.

Tang C, Wang M, Liu J, Zhang C, Li L, Wu Y Biomedicines. 2022; 10(12).

PMID: 36552026 PMC: 9775671. DOI: 10.3390/biomedicines10123270.

References
1.
Yu S, Nissaisorakarn P, Husain I, Jim B . Proteinuric Kidney Diseases: A Podocyte's Slit Diaphragm and Cytoskeleton Approach. Front Med (Lausanne). 2018; 5:221. PMC: 6141722. DOI: 10.3389/fmed.2018.00221. View

2.
Yan K, Khoshnoodi J, Ruotsalainen V, Tryggvason K . N-linked glycosylation is critical for the plasma membrane localization of nephrin. J Am Soc Nephrol. 2002; 13(5):1385-9. DOI: 10.1097/01.asn.0000013297.11876.5b. View

3.
Lim A, Tesch G . Inflammation in diabetic nephropathy. Mediators Inflamm. 2012; 2012:146154. PMC: 3432398. DOI: 10.1155/2012/146154. View

4.
Huber T, Kottgen M, Schilling B, Walz G, Benzing T . Interaction with podocin facilitates nephrin signaling. J Biol Chem. 2001; 276(45):41543-6. DOI: 10.1074/jbc.C100452200. View

5.
Adhikary L, Chow F, Nikolic-Paterson D, Stambe C, Dowling J, Atkins R . Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. Diabetologia. 2004; 47(7):1210-1222. DOI: 10.1007/s00125-004-1437-0. View